JP2017538407A5 - - Google Patents

Download PDF

Info

Publication number
JP2017538407A5
JP2017538407A5 JP2017529043A JP2017529043A JP2017538407A5 JP 2017538407 A5 JP2017538407 A5 JP 2017538407A5 JP 2017529043 A JP2017529043 A JP 2017529043A JP 2017529043 A JP2017529043 A JP 2017529043A JP 2017538407 A5 JP2017538407 A5 JP 2017538407A5
Authority
JP
Japan
Prior art keywords
polypeptide
disease
amino acid
seq
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017529043A
Other languages
English (en)
Japanese (ja)
Other versions
JP6730988B2 (ja
JP2017538407A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/063476 external-priority patent/WO2016090022A1/en
Publication of JP2017538407A publication Critical patent/JP2017538407A/ja
Publication of JP2017538407A5 publication Critical patent/JP2017538407A5/ja
Application granted granted Critical
Publication of JP6730988B2 publication Critical patent/JP6730988B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017529043A 2014-12-03 2015-12-02 グリコシル化シグナルを欠く改変バクテリオファージg3pアミノ酸配列を含むポリペプチド Expired - Fee Related JP6730988B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462087052P 2014-12-03 2014-12-03
US62/087,052 2014-12-03
PCT/US2015/063476 WO2016090022A1 (en) 2014-12-03 2015-12-02 Polypeptides comprising a modified bacteriophage g3p amino acid sequence lacking a gylcosylation signal

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020026300A Division JP2020073610A (ja) 2014-12-03 2020-02-19 グリコシル化シグナルを欠く改変バクテリオファージg3pアミノ酸配列を含むポリペプチド

Publications (3)

Publication Number Publication Date
JP2017538407A JP2017538407A (ja) 2017-12-28
JP2017538407A5 true JP2017538407A5 (https=) 2019-01-10
JP6730988B2 JP6730988B2 (ja) 2020-07-29

Family

ID=55273507

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017529043A Expired - Fee Related JP6730988B2 (ja) 2014-12-03 2015-12-02 グリコシル化シグナルを欠く改変バクテリオファージg3pアミノ酸配列を含むポリペプチド
JP2020026300A Withdrawn JP2020073610A (ja) 2014-12-03 2020-02-19 グリコシル化シグナルを欠く改変バクテリオファージg3pアミノ酸配列を含むポリペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020026300A Withdrawn JP2020073610A (ja) 2014-12-03 2020-02-19 グリコシル化シグナルを欠く改変バクテリオファージg3pアミノ酸配列を含むポリペプチド

Country Status (20)

Country Link
US (2) US10722551B2 (https=)
EP (1) EP3227313B1 (https=)
JP (2) JP6730988B2 (https=)
KR (1) KR20170085132A (https=)
CN (1) CN107250154A (https=)
AR (1) AR102890A1 (https=)
AU (1) AU2015358504A1 (https=)
BR (1) BR112017011530A2 (https=)
CA (1) CA2969128A1 (https=)
DK (1) DK3227313T3 (https=)
EA (1) EA201791212A1 (https=)
ES (1) ES2910017T3 (https=)
IL (1) IL252426A0 (https=)
MX (1) MX2017007059A (https=)
PH (1) PH12017501004A1 (https=)
PL (1) PL3227313T3 (https=)
PT (1) PT3227313T (https=)
SG (1) SG11201704427YA (https=)
TW (1) TW201632542A (https=)
WO (1) WO2016090022A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114748605A (zh) 2011-11-29 2022-07-15 普罗克拉拉生物科学股份有限公司 噬菌体基因3蛋白组合物及作为淀粉样蛋白结合剂的用途
CN104870008B (zh) 2012-10-02 2019-10-01 普罗克拉拉生物科学股份有限公司 噬菌体的p3融合蛋白作为淀粉样蛋白结合剂的用途
KR20160010618A (ko) 2013-05-28 2016-01-27 뉴로페이지 파마슈티컬즈, 인크. 감소된 면역원성을 갖는 개질된 박테리오파아지 g3p 아미노산 서열을 포함하는 폴리펩티드
PL3227313T3 (pl) 2014-12-03 2022-05-09 Proclara Biosciences, Inc. Polipeptydy zawierające zmodyfikowaną sekwencję aminokwasową bakteriofaga g3p pozbawioną sygnału glikozylacji
EP3806884B1 (en) * 2018-06-15 2023-08-02 Amyl Therapeutics General amyloid interaction motif (gaim)
CN120641092A (zh) 2022-12-02 2025-09-12 阿尔泽恩股份有限公司 用于用曲米沙特治疗神经变性病症的方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
ATE194384T1 (de) 1989-09-12 2000-07-15 Hoffmann La Roche Tnf-bindende proteine
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
DK0575545T3 (da) 1991-03-15 2003-09-15 Amgen Inc Pegylering af polypeptider
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DE69334070T2 (de) 1992-05-26 2007-01-04 Immunex Corp., Thousand Oaks Neue zytokine die cd30 binden
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
WO2000034317A2 (en) 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US8022270B2 (en) 2000-07-31 2011-09-20 Biolex Therapeutics, Inc. Expression of biologically active polypeptides in duckweed
US7189830B2 (en) 2001-02-19 2007-03-13 Merck Patent Gmbh Anti-KSA/IL-2 fusion proteins with reduced immunogenicity
MXPA03008032A (es) 2001-03-08 2003-12-04 Merck Patent Gmbh Factor de estimulacion de colonias de granulocitos- macrofagos modificado con inmunogenicidad reducida.
DE10238846A1 (de) 2002-08-20 2004-03-04 Nemod Immuntherapie Ag Aktive Fusionsproteine und Verfahren zu ihrer Herstellung
EP1853285B1 (en) 2005-02-01 2011-03-16 Ramot at Tel-Aviv University Ltd. Method for treating inflammation associated with amyloid deposits and brain inflammation involving activated microglia
MX2008010612A (es) 2006-02-15 2009-03-20 Ramot At Tel Aviv University Bacteriofago filamentoso que exhibe proteina a como aglutinante de anticuerpos e inmunocomplejos para el suministro hacia el cerebro.
US20090304726A1 (en) 2006-02-15 2009-12-10 Ramot At Tel Aviv University Ltd. Viral display vehicles for treating multiple sclerosis
WO2007109733A2 (en) 2006-03-21 2007-09-27 The Johns Hopkins University Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
WO2007114139A1 (ja) 2006-04-06 2007-10-11 Fumiaki Uchiyama 新規繊維状ファージによるファージディスプレイ
EP2054515B1 (en) 2006-07-21 2012-01-11 Ramot at Tel-Aviv University Ltd. Use of a phage displaying a peptide from an adhesion protein for treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates
EP2080138A2 (en) 2006-10-11 2009-07-22 Antitope Limited T cell epitope databases
WO2009143470A1 (en) 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Method for treating disease characterized by plaque
RU2011125971A (ru) 2008-11-24 2012-12-27 Рамот Эт Тель-Авив Юниверсити Лтд. Способ лечения болезни паркинсона
WO2011084714A2 (en) 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
BR112013023040A2 (pt) 2011-03-11 2018-10-23 Univ Ramot bacteriófago filamentoso, composição farmacêutica, e, métodos para reduzir a formação de fibrilas de proteína tau ou para desagregar fibrilas pré-formadas de proteína tau em um paciente, e para tratar uma tauopatia degenerativa.
CN114748605A (zh) 2011-11-29 2022-07-15 普罗克拉拉生物科学股份有限公司 噬菌体基因3蛋白组合物及作为淀粉样蛋白结合剂的用途
CN104870008B (zh) 2012-10-02 2019-10-01 普罗克拉拉生物科学股份有限公司 噬菌体的p3融合蛋白作为淀粉样蛋白结合剂的用途
KR20160010618A (ko) * 2013-05-28 2016-01-27 뉴로페이지 파마슈티컬즈, 인크. 감소된 면역원성을 갖는 개질된 박테리오파아지 g3p 아미노산 서열을 포함하는 폴리펩티드
PL3227313T3 (pl) 2014-12-03 2022-05-09 Proclara Biosciences, Inc. Polipeptydy zawierające zmodyfikowaną sekwencję aminokwasową bakteriofaga g3p pozbawioną sygnału glikozylacji

Similar Documents

Publication Publication Date Title
JP2017538407A5 (https=)
JP2016526044A5 (https=)
JP2012530055A5 (https=)
EP2361638B1 (en) A beta 1-42 specific monoclonal antibodies with therapeutic properties
JP6029280B2 (ja) D−ペプチドを有する抗−アミロイドβ−ペプチド抗体を製造するための組成物
US8440799B2 (en) Methods of purifying anti A β antibodies
Huang et al. Structure-specific effects of protein topology on cross-β assembly: studies of insulin fibrillation
CN108431044A (zh) 抗age抗体及其使用方法
JP6283366B2 (ja) アミロイド結合剤としてのバクテリオファージ融合タンパク質のp3の使用
US11723951B2 (en) Polypeptides comprising a modified bacteriophage G3P amino acid sequence lacking a glycosylation signal
US12247055B2 (en) General amyloid interaction motif (GAIM)
WO2020069050A2 (en) Methods of treating neurodegenerative diseases
Tai et al. The tau oligomer antibody APNmAb005 detects early-stage pathological tau enriched at synapses and rescues neuronal loss in long-term treatments
JP2021527407A5 (https=)
CN101325972B (zh) 具有治疗性质的Aβ1-42特异性单克隆抗体
CA3102841C (en) General amyloid interaction motif (gaim)
US20110002945A1 (en) Use of immunoglobulin heavy and light chains or fragments thereof to bind to aggregated amyloidogenic proteins
Wu et al. Conformation-dependent antibodies as tools for characterization of amyloid protein aggregates
HK40110180A (en) General amyloid interaction motif (gaim)
Griner Cross Amyloid interfaces of Amyloid Beta
HK40113703A (zh) 神经变性疾病的治疗剂
HK40049127B (en) General amyloid interaction motif (gaim)
HK40049127A (en) General amyloid interaction motif (gaim)
HK1124532B (zh) 具有治疗性质的Aβ1-42特异性单克隆抗体
HK1161141B (en) A beta 1-42 specific monoclonal antibodies with therapeutic properties